Impact of multiple sclerosis relapses on progression diminishes with time
- PMID: 19890070
- PMCID: PMC2881858
- DOI: 10.1212/WNL.0b013e3181c1e44f
Impact of multiple sclerosis relapses on progression diminishes with time
Abstract
Objective: The relationship between relapses and long-term disability in multiple sclerosis (MS) remains to be fully elucidated. Current literature is conflicting and focused on early relapses. We investigated the effects of relapses at different stages on disability progression.
Methods: We conducted a retrospective review of 2,477 patients with definite relapsing-onset MS followed until July 2003 in British Columbia, Canada. Time-dependent Cox proportional hazards models examined the effect of relapses at different time periods (0-5; >5-10; >10 years postonset) on time to cane (Expanded Disability Status Scale [EDSS]) and secondary progressive MS (SPMS). Findings were derived from hazard ratios with 95% confidence intervals (CIs), adjusted for sex, onset age, and symptoms.
Results: Mean follow-up was 20.6 years; 11,722 postonset relapses were recorded. An early relapse (within 5 years postonset) was associated with an increased hazard in disease progression over the short term, by 48%; 95% CI 37%-60% for EDSS 6 and 29%; 95% CI 20%-38% for SPMS. However, this substantially lessened to 10%; 95% CI 4%-16% (EDSS 6) and 2%; 95% CI -2%-7% (SPMS) after 10 years postonset. The impact of later relapses (>5-10 years postonset) also lessened over time. Effects were modulated by age, impact being greatest in younger (<25 years at onset) and least in older (>or=35 years) patients where relapses beyond 5-years postonset typically failed to reach significance. Relapses during SPMS had no measurable impact on time to EDSS 6 from SPMS.
Conclusion: Relapses within the first 5 years of disease impacted on disease progression over the short term. However, the long-term impact was minimal, either for early or later relapses. Long-term disease progression was least affected by relapses in patients with an extended disease duration (>10 years) or already in the secondary progressive phase.
Figures



Comment in
-
Relapses in multiple sclerosis: important or not?Neurology. 2009 Nov 17;73(20):1612-3. doi: 10.1212/WNL.0b013e3181c17fb5. Epub 2009 Nov 4. Neurology. 2009. PMID: 19890072 No abstract available.
Similar articles
-
Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis.Mult Scler. 2020 Jul;26(8):924-935. doi: 10.1177/1352458519848090. Epub 2019 May 16. Mult Scler. 2020. PMID: 31094285
-
Natural history of secondary-progressive multiple sclerosis.Mult Scler. 2008 Apr;14(3):314-24. doi: 10.1177/1352458507084264. Epub 2008 Jan 21. Mult Scler. 2008. PMID: 18208898
-
Relapses and disability accumulation in progressive multiple sclerosis.Neurology. 2015 Jan 6;84(1):81-8. doi: 10.1212/WNL.0000000000001094. Epub 2014 Nov 14. Neurology. 2015. PMID: 25398229 Free PMC article.
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.Mult Scler Relat Disord. 2021 May;50:102778. doi: 10.1016/j.msard.2021.102778. Epub 2021 Jan 28. Mult Scler Relat Disord. 2021. PMID: 33592384 Review.
Cited by
-
Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis-from diagnosis to prediction of disease activity.Wien Med Wochenschr. 2022 Nov;172(15-16):337-345. doi: 10.1007/s10354-022-00912-7. Epub 2022 Feb 8. Wien Med Wochenschr. 2022. PMID: 35133530 Free PMC article. Review.
-
Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective.Int J MS Care. 2012 Fall;14(3):148-59. doi: 10.7224/1537-2073-14.3.148. Int J MS Care. 2012. PMID: 24453746 Free PMC article.
-
'No evidence of disease activity' - is it an appropriate surrogate in multiple sclerosis?Eur J Neurol. 2018 Sep;25(9):1107-e101. doi: 10.1111/ene.13669. Epub 2018 May 28. Eur J Neurol. 2018. PMID: 29687559 Free PMC article. Review.
-
Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.Dis Markers. 2013;35(6):687-99. doi: 10.1155/2013/484959. Epub 2013 Nov 10. Dis Markers. 2013. PMID: 24324285 Free PMC article. Review.
-
Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.Clinicoecon Outcomes Res. 2017 Apr 28;9:251-260. doi: 10.2147/CEOR.S130334. eCollection 2017. Clinicoecon Outcomes Res. 2017. PMID: 28496344 Free PMC article.
References
-
- Compston A, Coles AJ. Multiple sclerosis. Lancet 2002;359:1221–1231. - PubMed
-
- Waxman SG. Demyelinating diseases: new pathological insights, new therapeutic targets. N Engl J Med 1998;338:323–325. - PubMed
-
- Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253:98–108. - PubMed
-
- Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528–1532. - PubMed
-
- Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N. Contribution of relapses to disability in multiple sclerosis. J Neurol 2008;255:280–287. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases